Fig. 10: The anti-tumor efficacy of CEP was tested in vivo.

A Images of subcutaneous tumors in MFC BALB/c nude mice, as well as tumor volume (B) and tumor weight (C) (n = 4). D The changes in body weight of MFC BALB/c nude mice treated with different drugs (n = 4). E Pathological changes (HE staining) of important organs, including the heart, liver, spleen, and kidneys in MFC BALB/c nude mice treated with different groups (n = 4). Scale: 100 μm. F Expression of Ki67 and cleaved caspase3 in tumor tissues of different groups (n = 3) of MFC BALB/c nude mice (immunohistochemistry). Scale: 100 μm. Data were expressed as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, with significant differences from the control group.